Association of cyclophilins and cardiovascular risk factors in coronary artery disease.
cardiovascular disease
cardiovascular risk factors
cyclophilins
dyslipidemia
inflammation
type 2 diabetes
Journal
Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
12
2022
accepted:
16
02
2023
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
Cyclophilins are chaperone proteins that play important roles in signal transduction. Among them, cyclophilins A, B, C, and D were widely associated with inflammation and cardiovascular diseases. Cyclophilins A and C have been proposed as coronary artery disease biomarkers. However, less is known about their relationship with cardiovascular risk factors. Therefore, this study aimed to determine the association between cyclophilin A, B, C, and D and cardiovascular risk factors in coronary artery disease. Serum levels of cyclophilins were measured in 167 subjects (subdivided according to cardiovascular risk factors presence). This study reveals that cyclophilin A and C are elevated in patients regardless of the risk factors presence. Moreover, cyclophilin B is elevated in male patients with hypertension, type 2 diabetes, or high glucose levels. In addition, cyclophilins A, B, and C were significantly correlated with cardiovascular risk factors, but only cyclophilin B was associated with type 2 diabetes. The multivariate analysis strengthens the predictive value for coronary artery disease presence of cyclophilin A (>8.2 ng/mL) and cyclophilin C (>17.5 pg/mL) along with the cardiovascular risk factors tobacco, hypertension, dyslipidemia, and high glucose and cholesterol levels. Moreover, the risk of coronary artery disease is increased in presence of cyclophilin B levels above 63.26 pg/mL and with hypertension or dyslipidemia in male patients. Consequently, cyclophilins A and C serum levels are reinforced as useful coronary artery disease biomarkers, meanwhile, cyclophilin B is a valuable biomarker in the male population when patients are also suffering from hypertension or dyslipidemia.
Identifiants
pubmed: 36935755
doi: 10.3389/fphys.2023.1127468
pii: 1127468
pmc: PMC10014534
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1127468Informations de copyright
Copyright © 2023 Gegunde, Alfonso, Alvariño, Pérez-Fuentes, Bayón-Lorenzo, Alonso, Ocaranza-Sánchez, Abellás-Sequeiros, Santás-Álvarez, Vieytes, Juanatey-González and Botana.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Chem. 2019 Dec;65(12):1469-1470
pubmed: 31699703
Sci Rep. 2019 Jul 22;9(1):10576
pubmed: 31332225
Arterioscler Thromb Vasc Biol. 2018 May;38(5):986-993
pubmed: 29599134
Front Cardiovasc Med. 2021 Jun 28;8:707889
pubmed: 34262956
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34473650
Biol Chem. 2020 Oct 25;401(11):1199-1214
pubmed: 32769215
Circ J. 2013;77(2):447-55
pubmed: 23138189
Int Heart J. 2017 Aug 3;58(4):475-480
pubmed: 28717115
Diabetes Care. 2023 Feb 1;46(2):450-454
pubmed: 36478189
Am Heart J. 2021 Aug;238:75-84
pubmed: 33961830
Cardiovasc Diabetol. 2014 Feb 07;13:38
pubmed: 24502618
Front Endocrinol (Lausanne). 2017 Dec 22;8:360
pubmed: 29312150
Biochemistry. 2010 Feb 9;49(5):1042-52
pubmed: 20050698
Cardiovasc Diabetol. 2016 Nov 3;15(1):152
pubmed: 27809851
N Engl J Med. 2006 Dec 21;355(25):2631-9
pubmed: 17182988
Exp Cell Res. 2021 Mar 15;400(2):112514
pubmed: 33582093
Cardiovasc Res. 2014 Apr 1;102(1):17-23
pubmed: 24518139
Metabolites. 2022 Jan 24;12(2):
pubmed: 35208183
Semin Immunol. 2018 Dec;40:17-35
pubmed: 30287177
Eur Heart J. 2021 Sep 7;42(34):3227-3337
pubmed: 34458905
Diabetes Care. 2021 Nov;44(11):e192-e193
pubmed: 34531311
Front Physiol. 2020 Jun 17;11:595
pubmed: 32625108
J Cereb Blood Flow Metab. 2005 Mar;25(3):325-37
pubmed: 15647740
Antioxid Redox Signal. 2010 Mar 1;12(5):675-82
pubmed: 19747062
Front Immunol. 2016 Oct 24;7:452
pubmed: 27822214
Cardiovasc Res. 2015 Jun 1;106(3):353-64
pubmed: 25750190
J Cell Physiol. 2019 Aug;234(10):16812-16823
pubmed: 30790284
J Hypertens. 2014 Dec;32(12):2305-14
pubmed: 25259548
Virol J. 2017 Jun 15;14(1):114
pubmed: 28619100
Clin Chim Acta. 2018 Nov;486:162-167
pubmed: 30077639
Plant Signal Behav. 2013 Jan;8(1):e22734
pubmed: 23123451
Eur J Immunol. 2021 Aug;51(8):1968-1979
pubmed: 33864384
Arch Cardiol Mex. 2021 Sep 30;92(2):189-195
pubmed: 34594052
J Cancer. 2021 Jun 16;12(16):4993-5004
pubmed: 34234868
Front Endocrinol (Lausanne). 2022 Jun 15;13:898384
pubmed: 35784538
Lancet. 2016 Jan 16;387(10015):251-72
pubmed: 26510778
Am J Cardiol. 2013 Mar 15;111(6):804-10
pubmed: 23291088
J Ayub Med Coll Abbottabad. 2016 Oct-Dec;28(4):725-729
pubmed: 28586599
Mol Endocrinol. 2000 Aug;14(8):1175-86
pubmed: 10935542
Am J Pathol. 2009 Jan;174(1):297-308
pubmed: 19056847
Circ Res. 2019 Jan 18;124(2):315-327
pubmed: 30653442
Cardiol Res. 2020 Oct;11(5):319-327
pubmed: 32849967
Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):685-693
pubmed: 28153875
Int J Mol Sci. 2021 Apr 15;22(8):
pubmed: 33920897